Basic Information
| LncRNA/CircRNA Name | RP11-263F15.1 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pancreatic ductal adenocarcinoma |
| ICD-0-3 | C25.3 |
| Methods | Microarray, qPCR |
| Sample | cancer tissues |
| Expression Pattern | differential expression |
| Function Description | In conclusion, these data indicate that differentially expressed lncRNAs and mRNAs were involved in the carcinogenesis of PDAC, and RP11-263F15.1 may prove to be a potential biomarker for the diagnosis and prognostic prediction of PDAC.Pancreatic ductal adenocarcinoma (PDAC) remains one of the most devastating malignancies with a 5-year survival rate less than 5% 1. Early diagnosis in combination with comprehensive therapies including surgical resection, adjuvant chemotherapy and radiotherapy can increase the 5-year survival rate significantly 2. |
| Pubmed ID | 28928863 |
| Year | 2017 |
| Title | Microarray Analysis of the Expression Profile of Long Non-Coding RNAs Indicates lncRNA RP11-263F15.1 as a Biomarker for Diagnosis and Prognostic Prediction of Pancreatic Ductal Adenocarcinoma. |
External Links
| Links for RP11-263F15.1 | GenBank HGNC NONCODE |
| Links for pancreatic ductal adenocarcinoma | OMIM COSMIC |